The positive outcome from the pre-clinical study is a significant milestone for Microbot Medical, suggesting potential for future growth as the company moves towards human clinical trials. The stock's movement is likely driven by investor optimism about the company's progress and potential market impact of the LIBERTY system. Additionally, the stock's visibility on social media and among retail traders could further fuel short-term price movement.